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Abstract
Background: There are few reports describing the epidemiology of visceral leishmaniasis (VL) in Somalia. Over the years
2002 to 2005, a yearly average of 140 patients were reported from the Huddur centre in Bakool region, whereas in 2006, this
number rose to 1002 patients. Given the limited amount of information on VL and the opportunity to compare features with
the studies done in 2000 in this part of Somalia, we describe the epidemiologic and clinical features of patients who
presented to the Huddur treatment centre of Bakool region, Somalia, using data routinely collected over a five-year
observation period (2002–2006).
Methodology: Methods used included the analysis of routine data on VL cases treated in the Huddur treatment centre,
a retrospective study of records of patients admitted between 2004 and 2006, community leaders interviews, and analysis of
blood specimens taken for parasite species identification in Antwerp Institute of Tropical Medicine.
Principal Findings: A total of 1671 VL patients were admitted to the Huddur centre from January 2002 until December
2006. Nearly all patients presented spontaneously to the health centre. Since 2002, the average patient load was stable, with
an average of 140 admissions per year. By the end of 2005, the number of admissions dramatically increased to reach a 7-
fold increase in 2006. The genotype of L. donovani identified in 2006 was similar to the one reported in 2002. 82% of total
patients treated for VL originated from two districts of Bakool region, Huddur and Tijelow districts. Clinical recovery rate was
93.2% and case fatality rate 3.9%.
Conclusions: After four years of low but constant VL case findings, a major increase in VL was observed over a 16-month
period in the Huddur VL centre. The profile of the patients was pediatric and mortality relatively low. Decentralized
treatment centers, targeted active screening, and community sensitization will help decrease morbidity and mortality from
VL in this endemic area. The true magnitude of VL in Somalia remains unknown. Further documentation to better
understand transmission dynamics and thus define appropriate control measures will depend on the stability of the context
and safe access to the Somali population.
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Introduction
Visceral leishmaniasis (VL) is a vector-borne parasitic disease
caused by Leishmania donovani. According to WHO, over the last 15
years, endemic regions have been extending and there has been
a sharp increase in the number of recorded cases of the disease.
For example, in eastern African countries it has caused epidemic
outbreaks like the ones that occurred in Southern Sudan from
1984–1994 [1], in North-eastern Kenya and South-eastern
Ethiopia in 2000–1, in eastern Sudan from 1996–97 [2], in
Ethiopia and Eritrea in 1997–98 [3]. Much of VL is concentrated
in East Africa [4] yet little has been reported from the endemic
parts of Somalia.
Different profiles of patients with VL and outcomes have been
described in Africa. In Ethiopia VL is commonly observed as an
opportunistic infection in HIV infected adults with documented
mortality rates up to18.5% [5]. In Western Upper Nile, Sudan, the
majority of cases reported during a major outbreak from 1984 to
1994 were adults with death rates of 38–57% [1]. In other regions
of Sudan and in West Pokot of Uganda it presents mainly as
a pediatric problem [6]. In the endemic area of Baringo district in
Kenya changing lifestyle has led to a decreasing proportion of new
VL cases among men [7].
Areas of Somalia where VL has been reported include the
coastal areas in the south of the country [8,9], the area along the
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Shebelle river in the south of Somalia [10], Lower Juba region
(MSF, unpublished report), and Baidoa in Bay region [11].
Information on local vector behaviour and risk factors for infection
or disease in Somalia are very limited. In Somalia transmission is
thought to be anthroponotic similar to other endemic areas of the
region (Uganda, Southern Sudan, Kenya) [12,6]. A study in
Kenya revealed that transmission occurs in and around houses [7],
but whether this occurs in Somalia is unknown. Termite hills are
the favoured breeding and resting sites of P.martini and they are
very common in Bakool [13,14].
The turmoil and factional fighting that followed the regime’s
overthrow in 1991 has left large parts of Somalia without any form
of health care. Even in 2006, the majority of health care provided
in South Central Somalia is carried out by non-governmental
organizations – but with very limited coverage of the Somali
population.
Bakol region is located in south-central Somalia, bordering
with Hiiraan region to the east, Bay region to the south, Gedo
region to the west, and Ethiopia to the north. Me´decins Sans
Frontie`res (MSF), a private, non-governmental organization, has
been working in Huddur, the capital of Bakool region since
2000, running a primary health care project consisting of
outpatient and in-patient departments, a therapeutic feeding
centre, a tuberculosis and a VL program. It has been the only
treatment centre for VL in Bakool region until 2006. The first
report published in the medical literature about VL in the Bakool
region in 2000–01 concluded from the pediatric profile of the
disease and information obtained from qualitative methods that
VL was since long endemic in that region [15]. The infectious
agent was confirmed as L.donovani, and entomological studies
revealed the presence of potential vectors, Phlebotomus martini and
Phlebotomus vansomerenae in Bakool region [16]. In the first year that
VL was treated in Huddur - between July 2000 and August 2001-
230 patients with VL were identified and treated [15]. Since 2002
the average caseload was stable at around 140 VL cases per year
until September 2005 when an increase in admissions was
observed. A total of 1002 patients representing a seven-fold
increase compared to previous years average were diagnosed in
year 2006.
Given the limited amount of information on VL and the
opportunity to compare features with the studies done in 2000 in
this part of Somalia, we describe the epidemiologic and clinical
features of patients who presented to the Huddur treatment centre
of Bakool region, Somalia, using data routinely collected over
a five-year observation period (2002–2006).
Methods
We describe the profile of VL in the Bakool region using several
methods: an analysis of epidemiological and clinical data from VL
cases treated in a VL-treatment centre, using a retrospective
analysis of case records, and analysis of blood specimens.
Setting and population
The Bakool region consists of 5 districts: Huddur, Tijeglow,
Rabdhure, Wajid and El-Berde, with a total estimated population
of 245 000. Most of the population of Bakool region have a semi-
nomadic lifestyle. The health centre in Huddur run by MSF serves
as the primary provider of medical care for the population living in
Huddur district. The population described in this report included
all patients diagnosed with VL at the Huddur health centre
between January 2002 and December 2006. All patients with VL
were treated as in-patients in the VL ward of the centre for the
entire duration of treatment of one month.
Definitions and data collection
A: Diagnosis, treatment, and discharge. Standardized
definitions for clinical and confirmed VL were used by the clinical
officers as per written clinical protocol (MSFB Field Guidelines for
VL, 2004). The clinical case definition of VL was: any patient
reporting a history of fever for more than 2 weeks in combination
with splenomegaly (palpable spleen), elevated temperature
(.38.5uC) or wasting on clinical exam, in whom malaria had been
excluded (negative Paracheck test or malaria treatment given).
In all patients meeting the clinical case definition, VL was
confirmed by a positive serological test, either direct agglutination
test (DAT, titre.1:800) or rK39 dipstick test (OptileishH, Diamed,
Switzerland) [17,18]. Serological diagnostic tests DAT and
Optileish were used, which have a sensitivity of 96.9% and
90.1% and a specificity of 93.7% and 93.1% respectively [19].
DAT was performed by the AMREF laboratories based in
Nairobi, Kenya from blood samples taken on filter paper. In
September 2004 a new diagnostic test, the rK39 dipstick, was
available and introduced in Huddur centre. It permitted
confirmation of VL in the field. Critically ill patients who had
features consistent with the clinical case definition but with
negative DAT and Optileish dipstick were put on treatment based
at the doctor’s discretion. Spleen aspiration was not performed
because it was considered too risky in this health setting. The
treatment for primary VL as per WHO guideline [20] was sodium
stibogluconate (SSG, produced by Albert David Ltd, Calcutta,
India) as a daily intramuscular injection at a dosage of 20 mg/kg
bodyweight for 30 days. Clinical features on admission and during
treatment were recorded for each patient in a standardized patient
file, from which the clinical information was encoded in an Access-
based software developed by Epicentre (42 bis Boulevard Richard
Lenoir, 75011 Paris).
Standardized definitions used for treatment outcome were
included in the clinical protocol: clinical recovery at the end of
treatment was defined as ‘no unexplained fever in the last two
weeks of the treatment, regression of the spleen, no bleeding,
weight gain and improved general well being’ (MSFB Field
Guidelines for VL, 2004).
B: Confirmation laboratory study. A convenience sample
of blood samples for species identification was taken from 17
Optileish positive patients admitted to the Huddur centre in
August 2006. This was done in order to compare the genotype of
the parasites detected in 2006, with the ones identified from
patient samples taken in year 2000 by MSF.
Author Summary
Our paper describes the epidemiological features of
visceral leishmaniasis in the Bakool region, South Central
Somalia, over the years 2004 to 2006. Since 2000, Me´decins
Sans Frontie`res has been providing care for patients
suffering from visceral leishmaniasis in Huddur, located in
a region endemic for visceral leishmaniasis. By the end of
2005, we witnessed a dramatic increase in the number of
patients admitted to the Huddur centre with visceral
leishmaniasis. In our paper, we provide a description of the
profile of patients admitted, thus giving an insight into the
epidemiology of visceral leishmaniasis in a part of the
world where relatively little has been documented and
where the true magnitude of this neglected disease
remains unknown.
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Samples were mixed with the same volume of AS1-buffer (Qiagen)
and sent to the Institute of Tropical Medicine, Antwerp, Belgium.
DNA extraction was performed with the QIAamp DNA blood Mini
Kit according to manufacturer’s instructions (Qiagen). The samples
were analyzed for the presence of Leishmania DNA by using
a Leishmania specific polymerase chain reaction (PCR) that amplifies
a 120 bp fragment of the parasite 18S ribosomal RNA gene
(Deborggraeve et al., unpublished results); this gene target has been
reported elsewhere for the sensitive and specific diagnostics of
Leishmania infections [21[. Species identification was done by two
species-specific PCR assays [22], L.infantum- and L.donovani-
specific, respectively targeting the E and F copies of the cysteine
proteinase B gene (cpb). These copies are situated at the 39 end of the
cpb gene cluster, and the type of gene is indicative for the species: L.
infantum strains are characterized by cpbE, while cpbF is found only
inL. donovani parasites [23]. Relative to cpbF, cpbE contains a deletion
of 39 nucleotides (13 amino acids), a feature used for the design of the
specific primers. The reference strains MHOM/MA/67/IT-
MAP263 (L. infantum) and MHOM/IN/2000/DEVI (L. donovani)
were used as controls. Species identification was confirmed by PCR-
restriction fragment length polymorphism (PCR-RFLP) [24].
Data entry and analysis
Since the VL treatment centre was established, data from
patients was collected by one national clinical officer who has been
working continuously on the program. The total number of
admissions was obtained from the main registration book of the
treatment centre. Demographic and clinical information were
collected from individual patient cards. Data from these patient
cards was entered routinely in the Access-based Kala Azar
Software that was first introduced in the MSF centre the field in
year 2004. Clinical records of patients admitted before 2004 were
not available for retrospective data entry. A total of 970 patient
records were entered into the software from January 2004 until
December 2006. This data was then exported to Excel program
for data management and analyses. We analyzed the number of
cases of VL detected over time, by age, sex, and geographical
origin. We compared clinical features between patients admitted
during the low case detection period before September 2005
(Jan04–Aug05) and the high case detection period starting in
September 2005 when the first increase in admissions was noticed
(Sep05–Dec06). Chi-squared test was used to compare propor-
tions. Student t-test was used to compare means.
Ethics
This outbreak investigation was viewed as a routine operational
response. Ethical issues were addressed the following way: we used
only routinely collected data in the process of monitoring
a treatment program, confidentiality of clinical and laboratory
patient information was maintained, patients were explained the
reason for taking additional blood samples and were asked for oral
consent, and blood samples analyzed in Antwerp Tropical
Institute were only used only to detect the parasites and perform
species identification. There are no laboratories in the southern
Somalia doing parasitological tests. The Ethics Review Board
instituted by Me´decins Sans Frontie`res reviewed that relevant
ethical issues in this project were well considered.
Results
Treatment centre admissions
A total of 1671 VL patients were admitted for treatment in the
Huddur Health Centre from Jan 2002 until December 2006.
Except for 27 found during outreach activities, all patients
presented spontaneously to the health centre. See Table 1 for
the number of admissions per year and the number of clinical
records available. Clinical records which were entered in the Kala
azar Software in 2004–2006 were available for a total of 970
patients. The incomplete data entry in 2005–6 is attributed to the
loss of patient cards during the high workload period when record
keeping became secondary to patient care.
Figure 1 illustrates the number of VL patients admitted for
treatment in Huddur centre across time since January 2002.
After a period of relatively low caseload with usually fewer than
20 admissions per month (Jan02 until Oct04), there were 5
months of very low patient admissions due to the absence of the
expatriate team (Nov04 until Mar05), during which patients were
accepted on an exceptional basis. In September 2005 the
monthly case detection started increasing to reach two peaks of
over 100 admissions in March–April06 and in September06.
Although the number of admissions was dropping after
September 2006, the number of admissions in the last quarter
of 2006 still remained higher than what was observed in previous
years.
Information on place of origin was available for 905/970
patients. Although patients with VL originated from all 5 districts
of Bakool region as well as from Baidoa district of Bay region (6%),
the majority of patients originated from only 2 districts, Huddur
and Tijeglow throughout the years as seen in Figure 2.
Figure 3 shows the age and sex distribution for 969 patients.
Median age of patients was 3.8 years (inter-quartile range 2 to 5)
and overall boys represented 59.4% of all patients. No adults were
diagnosed.
Clinical features (Table 2)
From the 970 clinical series entered in the database, we had
laboratory results for 943 patients and out of these 916 (97.1%)
were serologically confirmed with either DAT or the Optileish
dipstick. Post Kala Azar dermal leishmaniasis was exceptional with
only 1 case diagnosed in 2006. The overwhelming majority of
patients admitted were new cases with only 6 clinical relapses
diagnosed in 2006 and none in 2005. The core clinical features of
VL were commonly observed: fever, splenomegaly, weight loss/
wasting, and clinical anemia. Cough, epistaxis, and vomiting were
frequently reported accompanying symptoms. Diarrhea, jaundice,
and lymph node enlargement were infrequent. Duration of illness
before first consultation was around 4 months. Variables which
showed significant differences in frequencies between patients
admitted during the low (Jan04–Aug05) and high case detection
period (Sep05–Dec06) included loss of appetite, moderate malnu-
trition, clinical fever on admission, edema, and average spleen size
on admission. Moderate malnutrition, as measured by a Middle
Table 1. Number of VL patient admissions per year and







2003 107 5 (5%)
2004 117 117 (100%)
2005 270 166 (61%)
2006 1002 682 (68%)
doi:10.1371/journal.pntd.0000085.t001
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Upper Arm Circumference (MUAC) less than 126 mm on
admission, was much less prevalent among patients during the low
case detection period compared to the high one (42.0% compared to
86.3%; P-value,0.001). The proportion of patients with clinical
fever (.37.5uC) measured at admission was higher during the low
case detection period than the high case detection period (85.6%
compared to 61.2%; P-value,0.001). Average spleen size was higher
during low case detection period compared to the high one (8.5 cm
compared to 6.4 cm; P-value,0.001). Hepatomegaly was more
frequent in low case detection period than the high one (54.8%
compared to 22.7%; P-value,0.001) but data was only available for
42 patients during the low case detection period.
Treatment and outcomes
Information on treatment outcome was available for 925 of the
970 case series studied (95.4%). A total of 36 deaths were recorded
in the case series from January 2004 to December 2006, giving an
overall case-fatality rate of 3.9%. Clinical recovery rate was 93.2%
(862/925). A total of 27 patients defaulted (2.9%).
Parasite characterization
DNA of Leishmania spp. was found in 12 of the 17 samples taken
from Optileish positive patients under SSG treatment (range of 1
to 9 days of treatment). In 3 of them species identification was
reached and confirmed the presence of L.donovani. The 12 samples
Figure 1. Number of VL cases diagnosed in MSF centre in Huddur from January 2002 to December 2006.
doi:10.1371/journal.pntd.0000085.g001
Figure 2. District of origin of VL patients treated in Huddur centre, Bakool region, Somalia, 2004–2006.
doi:10.1371/journal.pntd.0000085.g002
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Figure 3. Age and sex of VL patients admitted in Huddur centre, Bakool, Somalia, 2004–2006.
doi:10.1371/journal.pntd.0000085.g003
Table 2. History and clinical features on admission for VL during the low (Jan04–Aug05) and high case detection periods (Sep05–






Average duration of illness before admission 4.3 months (N = 131) 3.8 months (N = 810) P = 0.09
History of fever 138/140 (98.6%) 811/820 (98.9%) P= 0.49
History of epistaxis 21/74 (28.4%) 198/721 (27.5%) P= 0.97
Loss of appetite 53/62 (85.5%) 551/749 (73.6%) P,0.001
Cough 113/132 (85.6%) 681/790 (86.2%) P= 0.85
Diarrhea 6/133 (4.5%) 69/806 (8.6%) P= 0.11
Vomiting 20/133 (15.0%) 169/805 (21.0%) P= 0.11
Average MUAC* (mm) 123.8 (Range: 96–168) 123.6 (Range: 78–170) P= 0.87
MUAC ,110 mm (severe malnutrition) 14/119 (11.8%) 86/630 (13.6%) P= 0.58
MUAC ,126 mm (moderate malnutrition) 50/119 (42.0%) 544/630 (86.3%) P,0.001
Average Weight (Kg) 11.5 (Range: 6.5–24.0) 10.8 (Range: 4.2–35.0) P= 0.032
Clinical fever (.37.5uC) 125/146 (85.6%) 501/818 (61.2%) P,0.001
Average Temperature on admission (uC) 38.34 37.8 P,0.001
Clinical anemia 118/143 (82.5%) 624/789 (79.1%) P= 0.35
Jaundice 2/125 (1.6%) 8/293 (2.7%) P= 0.49
Edema 14/13 (10.8%) 101/468 (21.6%) P=0.006
Average Spleen size on admission (cm) 8.5 (N = 131) 6.4 (N = 717) P,0.001
Lymph node enlargement 0/14 (0%) 12/184 (6.5%) P= 0.40
Hepatomegaly 23/42 (54.8%) 86/378 (22.7%) P,0.001
MUAC: Middle Upper Arm Circumference.
doi:10.1371/journal.pntd.0000085.t002
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were negative with the L.infantum-specific PCR. The 9 negative
samples with the L.donovani-specific PCR were likely due to a lower
sensitivity of the species-specific PCR in comparison with the
diagnostic PCR. For 2 of the L.donovani positive samples, cpb PCR-
RFLP patterns could be visualised and appeared to be similar to
the ones encountered in the L.donovani samples taken in year 2000
[15]. PCR positive samples belonged to patients living in the
districts of Huddur, Tijeglow, and Baidoa district of Bay region.
Discussion
This report describes the pattern of VL admissions over a five-
year period and the clinical characteristics and outcomes of 970
patients treated for VL in Huddur centre run by MSF in Somalia
over a 3-year period. After four years of low but constant passive
VL case finding in the endemic area of Bakool region, a major
increase in VL patient admission was observed over a 16-month
period in the Huddur centre. Although the reported number of
patients treated gives an underestimate of the real prevalence, the
trend in case detection clearly shows a sharp increase during the
past 16 month period (Sep05–Dec06). The number of patient
admissions was not found to be subject to seasonal variation. 82%
of total patients treated for VL originated from two districts of
Bakool region, Huddur and Tijeglow districts. This could reflect
a real clustering of VL as is known to occur within endemic areas.
For instance in Baringo district, Kenya, important differences in
seroprevalences between villages of the same endemic area were
documented [25]. There could be specific environmental and
social factors in the group of villages most affected in Tijeglow
district that favour transmission, but we have no information on it.
The pediatric profile of patients suggests that adults in the area
are immune and that we are dealing with an endemic pattern of
VL. The DNA pattern of L.donovani identified in 2006 was similar
to the one identified in 2000 [15] suggesting that the same parasite
strains remain circulating in the area over the period separating
the two sample collections. We cannot exclude the existence of
new parasite variants that would have been introduced in the area,
but to explore this possibility, further and extensive molecular
analysis would be required.
Better awareness amongst the population of the treatment
availability, spread by successfully treated patients, may have
contributed to the rise of detected cases. But the five-fold increase
in the monthly case detection implies that other factors came into
play and we cannot exclude a real increase in disease because the
prevalence of VL in the area is unknown.
Clinical features observed were typical of VL. The possible
increase in the population’s knowledge on the disease and on the
availability and reputation of treatment in Huddur, may have
contributed to the reduced average duration of sickness before
presentation: 4 months compared to 19 months in year 2000–1
[15]. This short duration of illness could explain the low case
fatality rate (3.9%) as found in Sudan [12]. We cannot explain the
observed sex difference among VL patients treated in Huddur
centre but suggest the boys had greater exposure to sand fly bites
of boys and/or possibly better access to care.
Although, statistically, there was no difference in duration of
illness, this may be due to lack of power, since the clinical
differences between patients of low and high caseload periods
suggest a shorter duration of illness in patients admitted during the
high caseload period. However, the difference in hepatomegaly is
probably artificial: missing values most likely represent negative
clinical findings, which if added to the denominator would reduce
the proportion of hepatomegaly during the low caseload period.
The fact that malnutrition was more common among patients
admitted during the high case detection period compared to the
low case detection period would suggest that a worsening in the
nutritional status among children in Tijeglow and Huddur districts
could have contributed to the increase in cases of of VL.
Malnutrition is a well known risk factor in the development of
VL disease [26].
Based on our experience certain measures could be implemen-
ted for improved care. Lack of transport and the long distances to
travel are known to limit the physical access to Huddur centre.
Opening other temporary treatment centers especially in the most
affected districts could improve access to care for VL patients.
Active screening for VL, when doing outreach work such as for
vaccination or nutritional screening, would help further increase
the number of cases detected and treated. Sadly, the instability in
the area due to armed conflict seriously thwarts these efforts.
Shorter treatment regimens are needed and would greatly help
improve acceptability of treatment and increase the treatment
completion rate.
Vector control and other preventive measures have not been
implemented but could improve control of VL in the area. For
instance the use of treated bed-nets to protect from the P.martini
bites, active at night time, which would not only reduce in-
household transmission of VL but also of malaria. Targeted
information and education of the population to increase awareness
could help increase early case detection and limit the use of
traditional remedies like abdominal scarification. Insecticidal
application to termite mounds could be a measure of targeted
control in the most affected villages.
There are a number of significant limitations to our data. One
was the lack of full clinical records. Although we cannot exclude
bias, there is no reason to believe that the missing patient charts
are associated with a particular patient characteristic or outcome
as missing data was likely due to reduced documentation of patient
charts due to high patient load. The constrained time and access to
remote villages did not allow for a prevalence survey in the whole
area affected by VL.
As exposure to sandfly varies from area to area, a case-control
study to determine the local risk factors of VL would be useful to
define targeted control measures. Additional documentation on
rain patterns, vector behaviour, and other risk factors for VL like
HIV co-infection would be useful in designing adapted interven-
tions to decrease morbidity and mortality.
Our experience suggests that VL is substantially underreported
in Bakool region and possibly in neighboring regions of southern
Somalia. The true magnitude of the problem of VL in Somalia is
likely to remain unknown and documentation and implementation
of effective interventions to control VL will be limited as long as
there will be no safe access to population and inexistent health care
services.
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